^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    AZD3463

    i
    Other names: AZD3463
    Company:
    AstraZeneca
    Drug class:
    ALK inhibitor, IGF-1R inhibitor
    Related drugs:
    4ms
    Development of a multi-indicator risk prediction model for cervical cancer associated with benzo[a]pyrene and nicotine exposure: A multi-omics study integrating toxicological analyses and molecular docking. (PubMed, Ecotoxicol Environ Saf)
    Risk prediction models based on multi-omics data and machine learning algorithms provide potential reference targets for prognosis prediction and personalised treatment of cervical cancer patients. The results of this study provide important insights into the understanding of the health risks of cervical cancer associated with Benzo[a]pyrene and Nicotine exposures and the development of preventive and therapeutic strategies for cervical cancer, which may contribute to the development of precision medicine for cervical cancer.
    Journal
    |
    SLAMF6 (SLAM Family Member 6)
    |
    docetaxel • Zarnestra (tipifarnib) • AZD3463 • AT7519
    5years
    Effects of rapamycin and AZD3463 combination on apoptosis, autophagy, and cell cycle for resistance control in breast cancer. (PubMed, Life Sci)
    In the combination of rapamycin with AZD3463, the expression of CDKN1B, PTEN, FOXO3, and APC genes increases, and the expression of PRKCB and PIK3CG genes decreases. Our results showed that the use of AZD-RAPA reduced the resistance of cancer cells to treatment and it leads cancer cells to apoptosis.
    Journal
    |
    ALK (Anaplastic lymphoma kinase) • PTEN (Phosphatase and tensin homolog) • PIK3CG (Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Gamma) • FOXO3 (Forkhead box O3) • CDKN1B (Cyclin dependent kinase inhibitor 1B)
    |
    PTEN expression • CDKN1B expression
    |
    sirolimus • AZD3463